金属蛋白酶-1组织抑制剂在重症哮喘中的作用。

IF 4.1 2区医学 Q2 ALLERGY

Allergy, Asthma & Immunology Research Pub Date : 2023-07-01 DOI:10.4168/aair.2023.15.4.416

Sang-Heon Kim

{"title":"金属蛋白酶-1组织抑制剂在重症哮喘中的作用。","authors":"Sang-Heon Kim","doi":"10.4168/aair.2023.15.4.416","DOIUrl":null,"url":null,"abstract":"https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"416-418"},"PeriodicalIF":4.1000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/69/aair-15-416.PMC10359650.pdf","citationCount":"0","resultStr":"{\"title\":\"Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma.\",\"authors\":\"Sang-Heon Kim\",\"doi\":\"10.4168/aair.2023.15.4.416\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.\",\"PeriodicalId\":7547,\"journal\":{\"name\":\"Allergy, Asthma & Immunology Research\",\"volume\":\"15 4\",\"pages\":\"416-418\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/69/aair-15-416.PMC10359650.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergy, Asthma & Immunology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4168/aair.2023.15.4.416\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4168/aair.2023.15.4.416","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma.

https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergy, Asthma & Immunology Research ALLERGY-IMMUNOLOGY

CiteScore

6.10

自引率

6.80%

发文量

审稿时长

>12 weeks

期刊介绍： The journal features cutting-edge original research, brief communications, and state-of-the-art reviews in the specialties of allergy, asthma, and immunology, including clinical and experimental studies and instructive case reports. Contemporary reviews summarize information on topics for researchers and physicians in the fields of allergy and immunology. As of January 2017, AAIR do not accept case reports. However, if it is a clinically important case, authors can submit it in the form of letter to the Editor. Editorials and letters to the Editor explore controversial issues and encourage further discussion among physicians dealing with allergy, immunology, pediatric respirology, and related medical fields. AAIR also features topics in practice and management and recent advances in equipment and techniques for clinicians concerned with clinical manifestations of allergies and pediatric respiratory diseases.